Recent Updates
Recently added Catalysts
ENVB Positive Sentiment Score: 75/100

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit [Microdose]

Wednesday, September 25, 2024 1 min read
Key Takeaway: Enveric Biosciences showcased their lead product candidate, EB-003, at the 7th Neuropsychiatric Drug Development Summit. The drug, a non-hallucinogenic analog of DMT, aims to treat anxiety and depression without the hallucinogenic effects. This breakthrough highlights the company's commitment to developing innovative neuroplastogenic therapeutics.
Price reaction · baseline $90.108 (2024-09-25T18:48:00.000Z) · hit during market hours · 1 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Enveric presented promising preclinical data for EB-003.
  • EB-003 aims to treat anxiety and depression effectively.
  • The drug is non-hallucinogenic, offering a safer alternative.

Full Press Release Details

In an era where mental health disorders such as depression and anxiety are among the leading causes of disability worldwide, the search for innovative treatments is more pressing than ever. The 7th Neuropsychiatric Drug Development Summit, held in Boston from September 24-26, 2024, highlighted an important breakthrough in this field. At the center of the event’s attention was Enveric Biosciences (NASDAQ: ENVB), a biotechnology company committed to developing novel neuroplastogenic small-molecule therapeutics. Enveric presented compelling preclinical data for their lead drug candidate, EB-003, a non-hallucinogenic, neuroplastogenic analog of N,N-Dimethyltryptamine (DMT), designed to treat anxiety and depression without the hallucinogenic effects commonly associated with traditional DMT-based therapies.
Full Article >>

Frequently Asked Questions

What is EB-003?

EB-003 is a non-hallucinogenic, neuroplastogenic analog of DMT developed by Enveric.

What disorders does EB-003 aim to treat?

EB-003 is designed to treat anxiety and depression.

Where was the data on EB-003 presented?

The data was presented at the 7th Neuropsychiatric Drug Development Summit in Boston.

What are the benefits of EB-003?

EB-003 offers a safer alternative to traditional DMT therapies by being non-hallucinogenic.

Tags: ENVB Viatris Investor Conferences Healthcare Enveric Biosciences EB-003 neuroplastogenic DMT anxiety treatment
Last updated: Sep 25, 2024

Biotech snapshot

Cash runway
$5M liquidity · $1M/mo burn
~4 mo
High dilution risk